Oppenheimer Reiterates Outperform on Tarsus Pharmaceuticals, Raises Price Target to $59
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Francois Brisebois has reiterated an Outperform rating on Tarsus Pharmaceuticals (NASDAQ:TARS) and increased the price target from $55 to $59.

February 28, 2024 | 12:48 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer has reiterated an Outperform rating on Tarsus Pharmaceuticals and raised the price target from $55 to $59.
The reiteration of an Outperform rating combined with an increased price target by a reputable analyst like Francois Brisebois suggests a strong bullish sentiment towards Tarsus Pharmaceuticals. This is likely to positively influence investor perception and could lead to a short-term increase in the stock price, as market participants may adjust their positions based on this new target and rating.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100